Welcome to our dedicated page for Celcuity news (Ticker: CELC), a resource for investors and traders seeking the latest updates and insights on Celcuity stock.
Celcuity Inc. develops targeted oncology therapies as a clinical-stage biotechnology company, with news centered on gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor for solid tumors. Company updates frequently cover Phase 3 VIKTORIA-1 data in HR+/HER2- advanced breast cancer, including PIK3CA wild-type and mutant cohorts and combination regimens with fulvestrant and palbociclib.
Recurring announcements also address FDA regulatory submissions and review status for gedatolisib, publications and medical-meeting presentations, quarterly financial results, corporate updates, investor conference participation, and board governance changes.
Celcuity Inc. (NASDAQ:CELC) will present at the LD 500 Investor Conference from September 1-4, 2020. CEO Brian Sullivan is scheduled to speak on September 2 at 11:00am ET on Track 1. The virtual presentation will be accessible via a live audio webcast, with an archived version available later. Celcuity focuses on developing next-generation diagnostics and therapeutic options for cancer patients through its innovative CELsignia platform. This conference provides a platform for one-on-one investor interactions to discuss the company's advancements.
Celcuity Inc. (NASDAQ:CELC) reported its second-quarter 2020 financial results, indicating a net loss of $2.20 million ($0.21 per share), up from $1.72 million ($0.17 per share) in Q2 2019. Operating expenses rose to $2.21 million, driven by increased R&D costs of $1.77 million. Cash and cash equivalents stood at $15.4 million as of June 30, 2020, expected to fund operations through 2021. The company remains focused on advancing its CELsignia diagnostic tests and anticipates announcing new collaborations by year-end, despite COVID-19-related delays in clinical trials.
Celcuity Inc. (NASDAQ:CELC) reported its second-quarter financial results for 2020, highlighting a net loss of $2.20 million, or $0.21 per share. Operating expenses rose to $2.21 million, driven by increased R&D costs of $1.77 million. Despite a cash burn rate remaining steady, cash and cash equivalents stood at $15.4 million as of June 30, expected to support operations through 2021. The company announced ongoing development of CELsignia tests and anticipates finalizing collaborations with pharmaceutical companies by year-end. Interim results from ongoing trials are expected in late 2021.